News | June 23, 2025
Cohance Lifesciences to sell CR Bio assets to Chromo Laboratories India for Rs. 16 Cr
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
Globally, BRUKINSA is approved in more than 70 countries
The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus
The initiative was announced at World Hypertension Congress, Chennai
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
The company has posted net profit of Rs. 1,414.44 crores for the Financial Year ended March 31, 2025
Standalone profit from operations for the quarter were Rs. 162 crores
ISPP will analyze health systems across states, identifying scalable models and actionable insights to strengthen India's healthcare delivery
The company has posted net profit of Rs. 1,767.63 crores for the Financial Year ended March 31, 2025
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
Subscribe To Our Newsletter & Stay Updated
